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Objective: We sought to fabricate a compliant engineered vascular graft (inner
diameter of approximately 4.5 mm and length of 6 cm) lined with endothelial
progenitor cells derived from circulating peripheral canine blood and to verify its
nonthrombogenicity potential in vivo.
Methods: Autologous circulating endothelial progenitor cells derived from the
peripheral veins of 6 adult mongrel dogs were isolated by using a density gradient
method. The cells were proliferated in vitro in EGM-2 culture medium, prelined on
the luminal surface of in situ–formed collagen type I meshes as an extracellular
matrix, and wrapped with a segmented polyurethane thin film with multiple micro-
pores as a compliant scaffold. After canine carotid arteries were bilaterally im-
planted with these grafts for 1 and 3 months, microscopic observation, histologic
staining, and immunochemical staining were performed to evaluate morphogenesis.
Results: After 33.3  10.5 days of culture in vitro, 4.2  1.2  106 endothelial
progenitor cells were obtained. Eleven of the 12 engineered vascular grafts were
patent. The grafts possessed smooth, glistening, and ivory-colored luminal surfaces
at the predetermined observation period up to 3 months. The intimal layer was
covered with confluent, cobblestone-like monolayered cells that were positively
stained with factor VIIIB–related antigen. The thickness of the neoarterial walls was
approximately 300 m at 3 months after implantation. A few smooth muscle cells
were observed in the medial tissue, and fibroblasts dominated the adventitial tissue.
Conclusion: Circulating endothelial progenitor cells could be a substitute source of
endothelial cells for endothelialization on small-diameter-vessel prostheses to en-
sure nonthrombogenicity.
Well-controlled tissue regeneration, healing, and vital functionunderlying the nonthrombogenic potential of tissue-engi-neered small-diameter vascular grafts can be achieved withcombinations of a proper selection of key element materials,a fabrication process technology of grafts, and a propercell-seeding technique and use of an appropriate source of
vascular cell types. It has been verified by many research groups that an autologous
endothelial cell (EC)–lined graft has proved antithrombogenicity. However, despite
the experimentally proved nonthrombogenicity of endothelialized hybrid grafts,
only a limited clinical application of such grafts has been reported, although Deutsch
and colleagues1 have been continuously implanting endothelialized grafts under
well-controlled clinical criteria using a defined technique. Although significant
advancement in vascular tissue engineering has been made with ECs, harvesting
ECs from a patient remains a problem of great concern.
On the other hand, recent studies evidenced that mature ECs and immature
endothelial-like cells float in circulating peripheral blood.2-5 Mature ECs are derived
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from those that fall out from the vascular wall (fall-out
ECs). The possibility of the existence of fall-out ECs has
been discussed over the years, and the fall-out hypothesis
recently has been verified experimentally.6 Endothelial
progenitor cells (EPCs), which fall out from the bone
marrow,3,4,7 are expected to have much higher prolifer-
ative potential than mature fall-out ECs.4 It is anticipated
that when EPCs are harvested from peripheral blood and
effectively proliferate, they serve as a very promising
alternative source of lining for cells. This eliminates the
need for surgical removal of the veins from which ECs
are usually harvested for tissue-engineered vascular
grafts. Recently, Kaushal and coworkers8 reported that
ovine EPC–seeded, decellularized porcine iliac vessels
have been remodeled to provide a functional vessel on
implantation and inherent functional properties, espe-
cially nitric oxide (NO) production in response to phys-
iologic stimuli, suggesting that EPCs are being differen-
tiated to mature ECs with implantation time and strongly
implying that the EPC is an alternative source of non-
thrombogenic cell lining.
In this study EPCs were harvested from canine periph-
eral blood and cultured. A compliant graft, which was
assembled with in situ–prepared collagen fiber meshes and
a microporous segmented polyurethane (SPU) tubular film,
was seeded with EPCs. The preliminary in vivo implanta-
tion study was conducted up to 3 months.
Materials and Methods
Harvesting and Culturing
The investigations were performed according to the “Principles of
Laboratory Animal Care” (formed by the National Society for
Medical Research) and the “Guide for the Care and Use of Lab-
oratory Animals” (National Institutes of Health publication no.
56-23, revised 1985). Peripheral blood (15 mL/sample) was col-
lected from 6 adult male mongrel dogs (weight, 27.5  3.1 kg) by
means of venipuncture, placed in 50-mL polypropylene centrifuge
tubes (IWAKI; Asahi Techno Glass, Tokyo, Japan), and anticoag-
ulated with heparin sodium (final concentration, 200 U/mL; Novo
Corp, Tokyo, Japan). The anticoagulated blood was diluted 1:2
with Hanks solution (Life Technologies Inc, Rockville, Md) con-
taining 1 mmol/L ethylenediamine tetraacetic acid and 0.5% bo-
vine serum albumin.
Mononuclear cells were isolated from the blood sample by
using a density gradient method with Histopaque-1077 (Sigma
Chemical Co, St Louis, Mo) according to the manufacturer’s
instructions. Cells obtained from the plasma-Histopaque-1077 in-
terface were washed 3 times by means of centrifugation at 250g for
10 minutes with MCDB 131 medium (Lite Technologies Inc),
containing 5 U/mL heparin sodium. The cells resuspended in
EGM-2 culture medium (Clonetics Inc, San Diego, Calif) were
inoculated into a culture dish precoated with type I collagen
(IWAKI, Asahi Techno Glass) and cultured in EGM-2 in a hu-
midified atmosphere of 5% CO2 at 37°C. The culture medium was
freshened twice a week. When the primary cells reached approx-
imately two thirds of the growth area, the cells were subcultured
with 0.01% trypsin (Life Technologies Inc) phosphate-buffered
Figure 1. Schematic of fabrication processes for the artificial vascular graft that is lined with an in situ–formed
type I collagen mesh as the matrix and wrapped with the SPU as the scaffold.
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saline solution and inoculated into a nonpretreated polystyrene
culture dish (IWAKI, Asahi Techno Glass) with a split ratio of 1:4
to 6. The immunohistologic staining of the rat monoclonal anti-
factor VIII–related antigen (Dako Corp, Glostrup, Denmark) and
mouse monoclonal anti-human Flk-1 (Santa Cruz Biotechnology
Inc, Santa Cruz, Calif), as well as the uptake of fluorescence-
labeled acetylated low-density lipoprotein (DiI-acetylated-LDL;
Biomedical Technologies Inc, Stought, Mass) were performed to
identify the subcultured cells. Diamino-fluorescein-2 diacetate
(DAF-2DA; Daiichi Pure Chemicals Co, Ltd, Tokyo, Japan),
which is a membrane-permeable, intracellular, NO-specific green
fluorescence indicator, was used to detect NO expression.9 EPCs
immersed in serum-free M199 containing 5 mol/L DAF-2DA for
60 minutes at 37°C were fixed and examined with a confocal laser
scanning microscope (Radiance 2000; Bio-Rad Laboratories Inc,
Hercules, Calif).
Cell Growth Curve
The number of subcultured cells in the culture dish was determined
by using the method described by Zilla and associates.10 Briefly,
by using a convert microscope, photographs were taken in 10
randomized areas at a magnification of 200 with instant film
(Polaroid 667, Cambridge, Mass). The number of cells in each
Figure 2. Blood-derived circulating EPCs in subculture: A, phase-contrast microscopy (original magnification
100); B, positive uptake of fluorescence-labeled acetylated low-density lipoprotein (confocal scanning micros-
copy; original magnification 400); C, positive immunochemical staining of factor VIII–related antigen (light
microscopy; original magnification 400); D, positive immunochemical staining of Flk-1 (light microscopy; original
magnification 400); E, intracellular NO production proved by means of intracellular staining with an NO-specific
indicator, DAF-2DA. Scale bars  100 m.
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photograph was counted. The cell density was calculated from the
average number of cells in the 10 photographs. The population
doubling time (PDT) was determined on the basis of the growth
curve (from the first day after subculture to the seventh day, n  3).
Fabrication of the Artificial Vascular Graft
The procedure followed for fabrication of the compliant artificial
vascular graft was our previously reported method.11 Briefly, a
cold mixture of 8 mL of M199 (Life Technologies Inc) culture
medium and 8 mL of acid-solubilized bovine dermal type I colla-
gen solution (0.3%, CELLGEN; Koken Corp, Tokyo, Japan) was
used to fill the space between the sheath (inner diameter of 15 mm)
and mandrel (outer diameter of 5 mm) of a tubular glass mold, as
shown in Figure 1. After subsequent thermal gelation at 37°C for
30 to 60 minutes, the sheath was removed. The resultant collagen
gel was allowed to stand in the medium for an additional week.
The collagen gel around the glass mandrel was squeezed to expel
water; wrapped with a 6-cm-long SPU (thickness of 100 m;
Shidame Co, Ltd, Tokyo, Japan) in which the pore-to-pore dis-
tance and the pore size were 1 mm and 100 m, respectively; and
then sutured by using the surgical continuous suture technique.
Details of the in-house preparation of micropores by using the
excimer laser ablation technique were described in our previous
work.12 The collagen gel was designed 3 mm longer than the SPU
film wrapping at both ends to prevent the formation of a false
aneurysm in the anastomotic sites after interposition. Protruding
parts were everted on both ends of the graft to encapsulate the
edges of the wrapping and were fixed with 4 sutures circumferen-
tially. The protocol for prelining the inner surface of the vascular
graft with EPCs was described in detail in our previous article.13
Briefly, after 2 mL of EPC-containing M199 solution (1.0  106
cells/mL) was poured into the lumen of the tissue, the graft was
placed horizontally and incubated at 37°C for 20 minutes. Then the
graft was rotated 90°, and additional EPC-containing M199 solu-
tion was poured into the lumen of the graft. This process was
repeated 4 times to achieve confluent density of ECs on the
luminal surface of the graft. After 2 days of incubation in M199
supplemented with 20% fetal bovine serum, an EPC-seeded graft
was obtained. An intraluminal mechanical support with 6 stainless
steel wires, which was described in our previous article,13 was
used when EPCs were seeded. The support was removed before
implantation.
Graft Implantation and Retrieval
General anesthesia was induced by means of injection of intra-
muscular ketamine (Ketaral 50, 15 mg/kg; Sankyo Co, Ltd, Tokyo,
Japan) and intravenous pentobarbital (Nembutal, 19 mg/kg; Dain-
ippon Pharmaceutical Co, Ltd, Osaka, Japan) and maintained by
means of intermittent injection of pentobarbital. Bilateral paratra-
cheal incisions were made along the trachea, and both common
carotid arteries were dissected, which yielded a segment approxi-
mately 10 cm in length. The end-to-end interposition of the pre-
pared artificial vascular graft was performed by running 6-0
polyprolene sutures into bilateral common carotid arteries of the
same dog from which the cells were isolated. Neither anticoagulant
nor antiplatelet agents were administered, except for the intraop-
erative heparin (100 U/kg) injected intravenously. The implanta-
tion observation period was predetermined to occur at 1 and 3
months. Graft patency was evaluated with manual palpation of the
pulse and direct observation of blood flow through the grafts at the
time of death. The graft, together with approximately 1- to 2-cm
native arteries at both ends, was fixed at 150 mm Hg of pressure
for 2 hours with 300 mL of fixative after flushing with 500 mL of
phosphate-buffered saline solution containing 100 U/mL heparin
for approximately 30 minutes to 1 hour. Then the graft was
longitudinally opened, photographed, and subjected to further
evaluation.
Scanning Electron Microscopic Examination
After postfixation in 1% osmium tetroxide, freeze-drying, and
subsequent coating by sputtering with platinum, the luminal sur-
faces of the samples were observed with a scanning electron
microscope (S-4000; Hitachi Corp, Tokyo, Japan).
Histologic Examination
Longitudinally prepared histologic sections were subjected to his-
tologic staining by using the following stains. First, hematoxylin-
and-eosin stain was used for general evaluation. The thickness of
the neoarterial wall, defined as the thickness of the tissue between
the EPC monolayer and the inner surface of the SPU film, was
measured from the distal anastomostic site to the midportion of the
graft interval of 0.5 cm. Five metric points for each graft were
projected with the aid of an image processor (original magnifica-
tion 100). Second, Masson trichrome stain was used for colla-
gen. Third, Alcian blue stain was used for proteoglycans. A mono-
clonal mouse antibody against an anti-factor VIII–related antigen
(for EPCs), anti-vimentin (for fibroblasts), and anti-smooth muscle
Figure 3. Growth curve of the circulating EPCs in subculture.
Each result is expressed as the mean  SD. The PDT in the
exponential stage was 23 to 29 hours.
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-actin (for smooth muscle cells), all of which were purchased
from Dako Corp, were used as primary antibodies, respectively,
and the biotin-avidin-peroxidase–labeled rat anti-rabbit IgG served
as the secondary antibody to identify the cell types in the neoar-
terial wall of the grafts.
Results
Mononuclear cells in peripheral blood isolated by means of
the centrifugal gradient density technique were cultured in
collagen-coated dishes. The majority of isolated mononu-
clear cells died within 2 to 3 weeks of culture. Colonies of
proliferating cells appeared at approximately 10 days, and
the primary culture of the surviving cells (n  6) was
continued for 17.3  6.5 days before subculture. The har-
vest rate of EPCs was approximately 15% (blood volume
per sample, 15 mL; total number of samples, 40; number of
generations of colony, 12; number of proliferative EPCs, 6).
Figure 2 demonstrates that the subcultured cells exhibited a
cobblestone-like morphology (Fig 2, A), positive uptake of
fluorescence-labeled acetylated low-density lipoprotein (Fig
2, B), and positive staining of the factor VIII–related antigen
(Fig 2, C) and Flk-1 (Fig 2, D). These cells also produced
NO intracellularly, which was proved by means of intracel-
lular staining with an NO-specific indicator, DAF-2DA (Fig
2, E). Our experiments showed that approximately 4.2 
1.2  106 EPCs were regularly obtained after 16  4 days
at 1 to 2 passages of subcultures. The PDT during the
exponential stage of cell proliferation, which started from 2
to 3 days after subculture and was semiquantatively deter-
mined, ranged from 23 to 29 hours, and the average PDT
calculated was 24.2  2.5 hours (Figure 3).
The hybrid vascular graft, which is composed of a con-
fluent EPC monolayer, dense collagen fiber mesh layer, and
microporous thin SPU film, was prepared according to the
schematic shown in Figure 1. Briefly, after a collagen gel
was formed in the interspace between a mold consisting of
an inner glass mandrel and an outer glass sheath, a micro-
porous SPU film was wrapped and squeezed tightly to expel
water out to form dense collagenous fiber meshes, as shown
in Figure 4. Collagen meshes completely covered the lumi-
nal surface of an SPU tube in which micropores were filled
with collagen meshes. After tight wrapping with the micro-
porous SPU film and suturing, the glass mandrel was care-
fully removed to leave a collagen mesh-lined SPU tube.
EPCs were seeded on the luminal surface of the graft and
Figure 4. Scanning micrograph of cross-sectional (A) and luminal (B) views of in situ–formed collagen mesh at
different magnifications (magnification is enlarged from left to right). Note that A in the cross-sectional view with
the lowest magnification denotes the dense collagen meshes formed in micropores when squeezed, and B denotes
a dense collagen mesh layer.
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further cultured for 1 week. The graft (dimensions of ap-
proximately 4.5 mm in diameter and 6 cm in length) was
connected to the carotid arteries of a dog from which
peripheral blood was withdrawn (Figure 5, A). There was
neither dilation along the graft nor stricture at either anas-
tomostic site at implantation. The projected implantation
period was scheduled to occur at 1 and 3 months. Eleven of
12 implanted grafts were completely patent. The smooth,
glistering, ivory-colored luminal surfaces, which are free of
thrombus, were observed for completely patent grafts at 3
months after implantation (Fig 5, B). One graft at 1 month
after implantation was dilated and partially occluded by the
thrombus, which might be due to loosening of the wrapping
sutures along the graft. The overall results of the implanted
grafts are summarized in Table 1.
Scanning electron microscopic observation showed that
the luminal surfaces of the grafts at 3 months after implan-
tation were covered with a confluent monolayer of cobble-
stone-like cells oriented parallel to the direction of arterial
flow (Figure 6, A and B). Immunohistologically, monolay-
ered cells on the luminal surface of the graft were positive
for the factor VIII–related antigen, as shown in Figure 7, A.
The ingrowth of the surrounding connective tissue through
the pores of the wrapping material was distinct (Figure 7,
B): cells strongly stained with anti-vimentin, probably iden-
tified as fibroblasts, invaded the pore in up to two thirds of
the neoarterial tissue and the thin layer in the luminal
region. Cells (defined as smooth muscle cells) positively
stained with smooth muscle cell–specific -actin, were ob-
served, with accumulation in the subtissue beneath the lu-
minal surface and distribution in the middle part of the
neoarterial tissue (Figure 7, C). Figure 8 shows a typical
morphogenetic feature of the tissue stained with hematox-
ylin and eosin (cells), Masson trichrome (collagen), and
Alcian blue (proteoglycan), indicating that tissue regenera-
tion proceeded well. The neoarterial walls have a thickness
of less than 200 m at 1 month after implantation and
approximately 300 m at 3 months after implantation (Fig-
ure 9). For both cases, there is little distance dependency of
neoarterial tissue formation (from the anastomotic site).
Discussion
Although extensive efforts have been made to develop a
vital, functioning, small-diameter artificial graft (inner di-
ameter of 5 mm), none have been realized clinically. On
the other hand, EC transplantation onto a synthetic artificial
graft by using either seeding or sodding techniques has
exhibited proved nonthrombogenic potential once a fully
endothelial monolayer that can withstand high pressure–
loaded arterial circulatory stress is formed on the luminal
surface of the artificial graft.1 Early successes achieving
long-term patency of EC-lined small-diameter grafts in an-
imal studies have not been followed by extensive use of this
technology in human subjects, except for by Zilla’s group,
who have been extensively implanting EC-seeded grafts
under well-defined clinical criteria and surgical procedures
and reported a more than 9-year follow-up study. The major
reasons for limited clinical realization must be the limited
number of ECs that can be obtained from a segment of
autologous vein, as well as questions concerning the re-
moval of viable vein segments from patients with vascular
diseases.
Figure 5. Macroscopic examination of EPC-seeded vascular
grafts: A, as implanted; B, the grafts had a smooth, glistening, and
ivory-colored luminal surface 3 months after implantation.
TABLE 1. Patency versus implantation period
Implantation period (mo) No. of implanted grafts
1 6 (1)*
3 6 (0)
*Number in parentheses represents the number of dilated or occluded
grafts.
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Alternative sources of autologous ECs are omental fat14
or adipose tissues.15 ECs from omental microvascularized
fat on an artificial graft have experimentally contributed to
endothelialization. However, it has been suggested that mi-
crovascular ECs from omental tissue are not of endothelial
origin.16 Sodding of fragmented vessel tissues has been
clinically used in Japan. On implantation, in situ cell sorting
resulted in the formation of EC lining on subvascular tissue
with implantation time.17 However, this method might not
be applicable to a small-diameter graft because massive
thrombus is formed at a very early phase of implantation.18
Recent studies have shown that mature fall-out ECs
detached from the vascular wall and bone marrow–derived
EPCs are circulating in the peripheral bloodstream.2-5 A
very small amount of bone marrow–derived EPCs circulat-
ing in blood, which are differentiated from CD34 cells,
form endothelial colonies.3-5,19 These cells uptake acety-
lated low-density lipoprotein, produce NO by means of
vascular endothelial growth factor stimulation, and express
von Willebrand factor, vascular endothelial cadherin, platelet
endothelial cell adhesion molecule 1, vascular endothelial
growth factor receptor 2 (Flk-1), and Tie-2 receptor.2,3,20
Figure 6. Scanning electron micrographic examination of the luminal surface of the graft 3 months after
implantation. The intima was covered with a confluent endothelial monolayer oriented parallel to the direction of
arterial blood flow. (Original magnification: A, 100; B, 1000.) Arrows indicate the direction of arterial blood flow.
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Before the existence of EPCs in circulating blood was
scientifically defined, several articles reported that im-
planted artificial devices were endothelialized for a long
period in vivo. The contribution of such ECs or EPCs to
endothelialization on impervious artificial grafts and ven-
tricular assist devices, both of which totally prevent transin-
terstitial tissue ingrowth, was observed in canine and sheep
models, respectively. Shi and coworkers6 reported that scat-
tered islands of endothelial-like cells and -actin–positive
smooth muscle cells were found beneath some of the endo-
thelial islands on the artificial graft. In addition, Frazier and
associates21 reported neointima that formed on the surface
of left ventricular assist devices is colonized by CD34
cells.
Our separate study with human EPCs revealed that an-
tiplatelet activity, as determined quantitatively on the basis
of the production rate of endothelial-type NO synthase and
prostacyclin, and fibrinolytic activity, as determined on the
basis of the production rate of the tissue plasminogen acti-
vator, were almost one third to one half of the former
Figure 7. Immunochemical staining of the neoarterial wall of EPC-seeded vascular grafts 3 months after implan-
tation: A, monoclonal antibody against factor VIII–related antigen (original magnification 200); B, monoclonal
antibody against vimentin (original magnification 200); C, monoclonal antibody against smooth muscle -actin
(original magnification 200). L, Luminal surface; S, SPU-contacting surface; P, wrapped polyurethane. Scale bars
 100 m.
Figure 8. Histologic examination of the neoarterial wall of EPC-seeded vascular grafts 3 months after implantation
(original magnification 200): A, hematoxylin and eosin staining; B, Masson trichrome staining; C, Alcian blue
staining. L, Luminal surface; S, SPU-contacting surface. Scale bars  100 m.
Cardiopulmonary Support and Physiology He et al
462 The Journal of Thoracic and Cardiovascular Surgery ● August 2003
CSP
activity of human ECs and almost equivalent for the latter.22
Therefore human EPCs might have nonthrombogenicity
close to that of ECs.
In this study canine EPCs harvested from circulating
peripheral blood and cultured according to a method similar
to that previously reported22 were obtained at a harvesting
rate of approximately 15% on single (15 mL of blood) or
multiple sampling. (Note that this rate is very high com-
pared with approximately 18% for human EPCs from 100
mL of blood, as shown in our experiment.22) The uptake of
low-density lipoprotein, the expression of factor VIII and
Flk-1, and the production of intracellular NO showed that
EPCs have the characteristic features of ECs. The patency
rate of EPC-based hybrid grafts was almost the same as
those of EC-based hybrid grafts, both of which use the same
scaffold (microporous SPU tube) and extracellular matrix
(collagen meshes).23 This pulsatile stress-responsive elasto-
meric tubular scaffold was found to have compliance close
to that of canine native carotid arteries, which was investi-
gated in detail in our previous articles.
In situ–formed collagen meshes as a cell-adhering matrix
penetrated into and filled micropores of the microporous
SPU wall scaffold, thus enabling exertion of the adhesion
strength of cell-matrix complexes on the SPU film, which
withstands continuously loaded pulsatile stress-inducing hy-
drodynamic shear stress and mechanical wall distension.
The transmural or transinterstitial tissue ingrowth from peri-
graft tissues through micropores was accompanied with
vimentin-positive cells (probably fibroblasts). At 3 months
after implantation, smooth muscle cells (-actin positive
cells) were accumulated beneath the luminal surface and
scattered distributed in the medial layer. Although we have
not yet determined quantitatively the nonthrombogenic po-
tentials of implanted EPCs, EPCs are expected to differen-
tiate into mature ECs as the implantation period proceeds.
This means that EPCs existing in circulating peripheral
blood can be an alternative cell source for vascular tissue–
engineered grafts. In fact, recent clinical studies have shown
that the infusion of the mononuclear cell fraction or CD34
cells, both of which contain EPCs, into ischemic tissues in
legs markedly improved the blood circulation in peripheral
regions caused by vasculogenesis.24 On the other hand, a
recent study of ovine EPC–seeded decellularized porcine
iliac vessels exhibited high patency, as well as contractile
activity and NO-mediated vascular relaxation, similar to
that of native arteries.8 Thus on the basis of these preceding
studies, EPC-based engineered grafts are clinically promis-
ing. Because isolation of EPCs and their mass proliferation
is a critical task for such an engineered graft, harvesting
from a patient’s bone marrow by mobilizing with the aid of
colony-stimulating factor and isolation and clonal prolifer-
ation of EPCs is more suited than those from peripheral
blood.
Dr He is on leave of absence from the Zhujiang Hospital
affiliated to the First Military Medical University of PLA, P.R.
China.
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